Trial Profile

A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Batoclimab (Primary)
Indications Graves ophthalmopathy
Focus Registrational; Therapeutic Use
Sponsors Immunovant

Most Recent Events

19 Dec 2024 Planned End Date changed from 1 Jan 2025 to 1 Dec 2025.
19 Dec 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
06 Aug 2024 According to an Immunovant media release, top-line data are expected to inform a decision regarding next steps for batoclimab in TED.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com